AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RECCE PHARMACEUTICALS LTD

0.370

+0.0154.23%

Volume:97.13K

Turnover:34.86K

Market Cap:113.04M

PE:-7.16

High:0.370

Open:0.355

Low:0.345

Close:0.355

52wk High:0.730

52wk Low:0.345

Shares:305.52M

Float Shares:168.89M

Volume Ratio:1.11

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.052

EPS(LYR):-0.052

ROE:-1277.62%

ROA:-82.75%

PB:-6.76

PE(LYR):-7.16

Loading ...

Overview Company News Filings

A AU$23m Market Cap Boost Pleasing ToRecce Pharmaceuticals Insiders

Simply Wall St.

Recce Pharmaceuticals Enters Proposed 10-Year Exclusive Licensing Nonbinding Agreement with Middle Eastern Firm, Shares Rise 10%

MT Newswires Live

BRIEF-Recce Pharmaceuticals Signs Middle East Licensing Term Sheet

Recce Pharmaceuticals Ltd - Parties Target Finalising Definitive Licensing Agreement Next Quarter

THOMSON REUTERS

Recce Pharmaceuticals Ltd - Licensee to Receive Exclusive Rights to R327g in Ksa, GCC, Egypt, Algeria, and Morocco

THOMSON REUTERS

Recce Pharmaceuticals Ltd - to Receive 30% of Net Selling Price and 6% Royalty on Sales Above US$50 Mln/Year

THOMSON REUTERS

Recce Pharmaceuticals Ltd - 10-Year Exclusive Agreement Includes Upfront Fee and Milestones up to US$3.5 Mln

THOMSON REUTERS

Recce Pharmaceuticals Ltd-Recce Signs Middle East Licensing Term Sheet

THOMSON REUTERS

Recce Pharmaceuticals Says Indonesian Regulator Completes Routine Regulatory Inspection of Phase Three Clinical Trial Site

MT Newswires Live

Recce Pharmaceuticals Secures Brazilian Family 4 Patent For Anti-Infectives

MT Newswires Live

Recce Pharmaceuticals Ltd - Hy Net Loss Attributable a$16.6 Mln

THOMSON REUTERS

Recce Pharmaceuticals Ltd-Change of Director's Interest Notices (X5)

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/RCE.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RCE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.37,"timestamp":1789020720000,"preClose":0.355,"halted":0,"volume":97134,"delay":0,"changeRate":0.042253521126760604,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":168893037,"shares":305520100,"eps":-0.0517,"marketStatus":"Not Yet Opened","change":0.015,"latestTime":"09-10 16:12:00 AEST","open":0.355,"high":0.37,"low":0.345,"amount":34861,"amplitude":0.070423,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0517,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.355,"openAndCloseTimeList":[[1788998400000,1789020000000]],"volumeRatio":1.1144460139943497,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RCE.AU","preClose":0.355,"auctionPrice":0.37,"auctionVolume":5869,"auction":3,"marketStatus":"盘后竞价","timestamp":1789020592219}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","floatShares":168893037,"roa":"-82.75%","roe":"-1277.62%","lyrEps":-0.0517,"volumeRatio":1.1144460139943497,"shares":305520100,"dividePrice":0,"high":0.37,"amplitude":0.070423,"preClose":0.355,"low":0.345,"week52Low":0.345,"pbRate":"-6.76","psRate":"11.94","week52High":0.73,"institutionHeld":0,"latestPrice":0.37,"eps":-0.0517,"divideRate":0,"volume":97134,"delay":0,"ttmEps":-0.0517,"open":0.355,"prevYearClose":0.65,"prevWeekClose":0.37,"prevMonthClose":0.375,"prevQuarterClose":0.405,"fiveDayClose":0.36,"twentyDayClose":0.375,"sixtyDayClose":0.48,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCE.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-04-15","symbol":"RCE.AU","defaultRemindTime":1744675200000,"type":"split","dateTimestamp":1744639200000,"forFactor":990476,"toFactor":1000000,"ratio":0.990476}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCE.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCE.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2638265050","title":"A AU$23m Market Cap Boost Pleasing ToRecce Pharmaceuticals Insiders","url":"https://stock-news.laohu8.com/highlight/detail?id=2638265050","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638265050?lang=en_us&edition=fundamental","pubTime":"2026-05-28 11:55","pubTimestamp":1779940518,"startTime":"0","endTime":"0","summary":"Insiders who bought Recce Pharmaceuticals Ltd ( ASX:RCE ) stock in the last 12 months were richly rewarded last week...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rce/recce-pharmaceuticals-shares/news/a-au23m-market-cap-boost-pleasing-torecce-pharmaceuticals-in","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-rce/recce-pharmaceuticals-shares/news/a-au23m-market-cap-boost-pleasing-torecce-pharmaceuticals-in","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638360575","title":"Recce Pharmaceuticals Enters Proposed 10-Year Exclusive Licensing Nonbinding Agreement with Middle Eastern Firm, Shares Rise 10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638360575","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638360575?lang=en_us&edition=fundamental","pubTime":"2026-05-27 12:23","pubTimestamp":1779855787,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  entered into a non-binding term sheet with a Middle Eastern pharmaceutical company for a proposed 10-year exclusive licensing arrangement covering the commercial sales and distribution of Recce's proprietary R327 topical gel for the treatment of diabetic foot infections, according to a Wednesday Australian bourse filing.The agreement covers Saudi Arabia, the United Arab Emirates, Kuwait, Oman, Bahrain, Qatar, Iraq, Egypt, Algeria, and Morocco. Recce will be responsible for the manufacture and supply of the R327 topical gel.The agreement is expected to include an upfront signing fee, together with milestone payments totalling up to $3.5 million. Recce is also expected to receive 30% of the net selling price, with an additional 6% annual royalty on net sales of over $50 million per year. The proposed selling price is $1,500 per treatment, subject to agreement with the regulatory authority in Saudi Arabia.The parties are collaborating to finalize and execute a defin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["EML","BK4161","RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638527896","title":"BRIEF-Recce Pharmaceuticals Signs Middle East Licensing Term Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2638527896","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638527896?lang=en_us&edition=fundamental","pubTime":"2026-05-27 09:52","pubTimestamp":1779846721,"startTime":"0","endTime":"0","summary":"BRIEF-Recce Pharmaceuticals Signs Middle East Licensing Term SheetMay 27  - Recce Pharmaceuticals Ltd RCE.AX:RECCE SIGNS MIDDLE EAST LICENSING TERM SHEET10-YEAR EXCLUSIVE AGREEMENT INCLUDES UPFRONT FEE AND MILESTONES UP TO US$3.5 MILLIONTO RECEIVE 30% OF NET SELLING PRICE AND 6% ROYALTY ON SALES ABOVE US$50 MILLION/YEARSIGNS NON-BINDING TERM SHEET WITH LEADING MIDDLE EASTERN PHARMACEUTICAL COMPANYPARTIES TARGET FINALISING DEFINITIVE LICENSING AGREEMENT NEXT QUARTERLICENSEE TO RECEIVE EXCLUSIVE RIGHTS TO R327G IN KSA, GCC, EGYPT, ALGERIA, AND MOROCCOFurther company coverage: RCE.AX ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260527:nTUE9KLFRS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638652957","title":"Recce Pharmaceuticals Ltd - Parties Target Finalising Definitive Licensing Agreement Next Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2638652957","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638652957?lang=en_us&edition=fundamental","pubTime":"2026-05-27 07:48","pubTimestamp":1779839337,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUE9KLFRS:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638575529","title":"Recce Pharmaceuticals Ltd - Licensee to Receive Exclusive Rights to R327g in Ksa, GCC, Egypt, Algeria, and Morocco","url":"https://stock-news.laohu8.com/highlight/detail?id=2638575529","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638575529?lang=en_us&edition=fundamental","pubTime":"2026-05-27 07:48","pubTimestamp":1779839337,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUE9KLFRS:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638529579","title":"Recce Pharmaceuticals Ltd - to Receive 30% of Net Selling Price and 6% Royalty on Sales Above US$50 Mln/Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2638529579","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638529579?lang=en_us&edition=fundamental","pubTime":"2026-05-27 07:48","pubTimestamp":1779839337,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUE9KLFRS:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638529573","title":"Recce Pharmaceuticals Ltd - 10-Year Exclusive Agreement Includes Upfront Fee and Milestones up to US$3.5 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2638529573","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638529573?lang=en_us&edition=fundamental","pubTime":"2026-05-27 07:48","pubTimestamp":1779839337,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUE9KLFRS:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638152958","title":"Recce Pharmaceuticals Ltd-Recce Signs Middle East Licensing Term Sheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2638152958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638152958?lang=en_us&edition=fundamental","pubTime":"2026-05-27 07:48","pubTimestamp":1779839337,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260526:nTUE9KLFRS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629059007","title":"Recce Pharmaceuticals Says Indonesian Regulator Completes Routine Regulatory Inspection of Phase Three Clinical Trial Site","url":"https://stock-news.laohu8.com/highlight/detail?id=2629059007","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629059007?lang=en_us&edition=fundamental","pubTime":"2026-04-21 10:26","pubTimestamp":1776738396,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  said the Indonesian National Agency of Drug and Food Control completed a comprehensive routine regulatory inspection of a phase three clinical trial site in Indonesia, with no findings noted that prevent the study from continuing, according to a Tuesday Australian bourse filing.The phase three clinical trial for the treatment of diabetic foot infections is advancing patient dosing, and it is on track to produce interim data from 155 patients.The firm's shares rose 2% in recent trading on Tuesday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621031534","title":"Recce Pharmaceuticals Secures Brazilian Family 4 Patent For Anti-Infectives","url":"https://stock-news.laohu8.com/highlight/detail?id=2621031534","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621031534?lang=en_us&edition=fundamental","pubTime":"2026-03-24 09:50","pubTimestamp":1774317009,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  said the Brazilian National Institute of Industrial Property formally granted the firm a Family 4 patent for its anti-infectives, expiring in 2041, according to a Tuesday Australian bourse filing.The patent relates to the process for preparation of the anti-infectives, as well as the use of its R327 and R529 therapy candidates, particularly in the treatment of bacterial infections and viral infections.It also relates to the administration of the anti-infectives by oral, inhalation, transdermal delivery, or by injection. They can also be delivered as an aerosol, gel, topical foam, or ointment.Its shares climbed 2% in recent trading on Tuesday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614815368","title":"Recce Pharmaceuticals Ltd -  Hy Net Loss Attributable a$16.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614815368","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614815368?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:02","pubTimestamp":1772175776,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nFWN3ZM2BA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613762992","title":"Recce Pharmaceuticals Ltd-Change of Director's Interest Notices (X5)","url":"https://stock-news.laohu8.com/highlight/detail?id=2613762992","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613762992?lang=en_us&edition=fundamental","pubTime":"2026-02-24 14:51","pubTimestamp":1771915900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUE2QB63D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":32,"code":"91000000","status":"200"}]}}